$2.48
4.98% yesterday
Nasdaq, Nov 25, 10:17 pm CET
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Sana Biotechnology Inc Stock price

$2.48
-1.28 34.04% 1M
-5.54 69.08% 6M
-1.60 39.22% YTD
-1.76 41.51% 1Y
-16.49 86.93% 3Y
-32.62 92.93% 5Y
-32.62 92.93% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.13 4.98%
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Key metrics

Market capitalization $553.71m
Enterprise Value $446.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.89
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-296.47m
Free Cash Flow (TTM) Free Cash Flow $-274.99m
Cash position $202.84m
EPS (TTM) EPS $-1.41
P/E forward negative
Short interest 31.74%
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sana Biotechnology Inc forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
57%
Hold
43%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 19 19
30% 30%
-
-19 -19
30% 30%
-
- Selling and Administrative Expenses 41 41
7% 7%
-
- Research and Development Expense 217 217
5% 5%
-
-277 -277
0% 0%
-
- Depreciation and Amortization 19 19
30% 30%
-
EBIT (Operating Income) EBIT -296 -296
3% 3%
-
Net Profit -306 -306
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
GlobeNewsWire
about 16 hours ago
SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Neutral
Seeking Alpha
7 days ago
Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's curr...
Neutral
GlobeNewsWire
18 days ago
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 328
Founded 2018
Website www.sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today